Expression of paxillin and FAK mRNA and the related clinical significance in esophageal carcinoma

Molecular Medicine Reports

Volumn 5, Issue 2, 2012, Pages 469-472

  Cai, Hong Xing ^a,b   Yang, Liu Cai ^a   Song, Xiang He ^a   Liu, Zhou Ru ^b   Chen, Yan Bo ^b   Dong, Guo Kai ^b  

^a Yancheng Health Vocational and Technical College   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Esophageal carcinoma; Focal adhesion kinase; Paxillin; RT PCR

Indexed keywords

FOCAL ADHESION KINASE; MESSENGER RNA; PAXILLIN;

ADULT; AGED; ARTICLE; CANCER INVASION; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; ESOPHAGEAL NEOPLASMS; FEMALE; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PAXILLIN; RNA, MESSENGER;

EID: 84862946847     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.664     Document Type: Article

References (13)

1. Iwasaki T, Nakata A, Mukai M, et al: Involvement of phosphorylation of Tyr-31 and Tyr-118 of paxillin in MM1 cancer cell migration. Int J Cancer 97: 330-335, 2002. (Pubitemid 34049023)
2. Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP and Chen RH: Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol 24: 10558-10572, 2004. (Pubitemid 39603116)
3. Das T, Bae YH, Wells A and Roy P: Profilin-1 overexpression upregulates PTEN and suppresses AKT activation in breast cancer cells. J Cell Physiol 218: 436-443, 2009.
4. Zou L, Jaramillo M, Whaley D, Wells A, Panchapakesa V, Das T and Roy P: Profilin-1 is a negative regulator of mammary carcinoma aggressiveness. Br J Cancer 97: 1361-1371, 2007. (Pubitemid 350114790)
5. Chang X, Hou X, Pan J, Fang K, Wang L and Han J: Investigating the pathogenic role of PADI4 in oesophageal cancer. Int Biol Sci 7: 769-781, 2011.
6. Chava S, Mohan V, Shetty PJ, Manolla ML, Vaidya S, Khan IA, Waseem GL, Boddala P, Ahuja YR and Hassan Q: Immunohistochemical evaluation of p53, FHIT, and IGF2 gene expression in esophageal cancer. Dis Esophagus: June 10, 2011, doi: 10.1111/j.1442-2050.2011.01213.x (Epub ahead of print).
7. Rao S, Welsh L, Cunningham D, Te-poele RH, Benson M, Norman A, Saffery C, Giddings I, Workman P and Clarke PA: Correlation of overall survival with gene expression profiles in a prospective study of resectable esophageal cancer. Clin Colorectal Cancer 10: 48-56, 2011.
8. Mitra SK and Schlaepfer DD: Intergrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18: 516-523, 2006. (Pubitemid 44332916)
9. Kim LC, Song L and Haura EB: Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6: 587-595, 2009.
10. Kim MS, Yoo NJ and Lee SH: Absence of paxillin gene mutation in lung cancer and other common solid cancers. Tumori 97: 211-213, 2011.
11. Chen JY, Tang YA, Huang SM, et al: A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res 71: 473-483, 2011.
12. Chatzizacharias NA, Kouraklis GP and Theocharis SE: Clinical significance of FAK expression in human neoplasia. Histol Histopathol 23: 629-650, 2008. (Pubitemid 351552349)
13. Li BZ, Lei W, Zhang CY, et al: Increased expression of paxillin is found in human oesophageal squamous cell carcinoma: a tissue microarray study. J Int Med Res 36: 273-278, 2008. (Pubitemid 351516609)